MedTrace Logo

Morphine, Dyspnea, Exercise and COPD

NCT01718496 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-09-24

No results posted yet for this study

Summary

The investigators are studying the effect of a single dose Opioid drug (Morphine) on dyspnea and exercise tolerance in COPD patients.

Conditions

Interventions

DRUG

Morphine

patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance

DRUG

Placebo

patients with advanced COPD on the other study arm will randomly receive Placebo

Sponsors & Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Dennis Jensen, Ph. D. · McGill University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01718496 on ClinicalTrials.gov